Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06068803
Other study ID # 23/SW/0067
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 14, 2023
Est. completion date September 30, 2025

Study information

Verified date September 2023
Source University of Bath
Contact Anna Nicholas
Phone +44 7724 303532
Email an915@bath.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomised, double-blinded, placebo-controlled trial is to investigate the immune, metabolic and cognitive effects of four weeks of daily ketone supplementation in adults aged 60 to 80 with stable health. The main objectives are to assess the effects of the intervention versus placebo on markers of metabolic health, inflammation, immune function, adipose tissue, and cognitive performance. Participants will undergo two weeks of baseline monitoring followed by a four-week supplementation period in which they will drink a ketone monoester drink or taste-matched placebo three times a day. During these periods, participants will record their diet and supplement intake and their physical activity and blood glucose will be monitored using wearable devices. At the beginning and end of the supplementation period, participants will undergo testing in the university physiology laboratories, involving blood, expired air and adipose tissue samples, as well as cognitive tests, physical tests and questionnaires.


Description:

Background: Research shows that ketones have beneficial effects on metabolism, inflammation and brain health in humans. In mice, they have also been shown to influence pathways involved in ageing. Ketones are natural molecules that are produced by the body when people fast (abstain from eating) for longer than 16-24 hours or eat a diet low in carbohydrates. It is now possible to consume ketones in the form of a drink. Aims: This study aims to investigate if consuming a ketone drink for four weeks improves immunometabolic and cognitive health in adults aged 60 to 80 years. The main objectives are to assess the effects of the intervention versus placebo on: 1. Markers of metabolic health, including glucose control, lipid profile, blood pressure and body composition; 2. Systemic inflammation, immune cell activation and pro-inflammatory cytokine production; 3. Gene expression and secretory profile of subcutaneous adipose tissue; and 4. Cognitive performance and physical function. Methods: The study is a randomised, double-blinded, placebo-controlled trial. Thirty participants (male and female) aged 60 to 80 years old with stable health will be recruited. Participants will undergo two weeks of baseline monitoring followed by a four-week supplementation period in which they will drink a ketone monoester drink or placebo three times a day. During these periods, participants will record their diet and supplement intake and their physical activity and blood glucose will be monitored using wearable devices. For two days in the supplementation period, participants will replicate their food consumption and physical activity so that they match two days in the baseline period (these are known as matched meal and activity days). At the beginning and end of the supplementation period, participants will come to the physiology laboratories at the University of Bath for testing. Here, measures will be taken of their body weight, body composition, blood pressure, cognitive function and physical function, as well as samples of expired air, fat tissue and blood for analysis. Sleep and quality of life will be assessed via questionnaires.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 30, 2025
Est. primary completion date September 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 80 Years
Eligibility Inclusion Criteria: - Age 60 to 80 years - Postmenopausal women must be >1 year since last menses - Able to provide informed consent - Willing and able to comply with all study procedures including randomisation into any of the experimental groups; maintenance of habitual dietary intake, exercise, medication and supplement use over the 28-day intervention period; blood draws and adipose tissue biopsies; and abstinence from alcohol (>24 h), food (>10 h) and strenuous exercise (>3 d) prior to trial days. Exclusion Criteria: - Living in a residential care home - Unstable or clinically active pulmonary, cardiac, hepatic, renal, endocrine, hematologic, immunologic, neurologic, psychiatric or biliary disorders. 'Unstable' refers to complications of a condition that are not controlled by medication or lifestyle and which require frequent monitoring and testing by a health professional. Stable chronic disease is not an exclusion criterion unless specified. - Diagnosed Type 1 or Type 2 Diabetes Mellitus - Diagnosed gastrointestinal condition which would potentially impact ability to consume study drink (e.g. inflammatory bowel disease, history of gastrointestinal ulcers or bleeding) - Diagnosed autoimmune condition - Previous major cardiovascular event (e.g. heart attack, stroke) - Past or current cancer diagnosis and treatment excluding non-melanoma skin cancers - Severe hypertension (systolic blood pressure =180 mmHg and/or diastolic blood pressure =120 mmHg), as defined by blood pressure measured at Visit 1 - Current tobacco or recreational drug use - Reported changes to use of thyroid, antihypertensive, antidepressant or statin medications within 30 days of Visit 1 - Taking medications that will interfere with the study outcomes - Known negative reaction to lidocaine anaesthetic and/or taking warfarin - Currently following a ketogenic diet or taking ketone supplements - Not weight stable in the prior 3 months (>5% weight change) - Unable to converse in English

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Ketone drink
Participants will consume three daily ketone monoester (KME) drinks (0.282g KME/kg body weight/ serving) for 4 weeks.
Placebo
Participants will consume three daily taste-matched calorie-free placebo drinks for 4 weeks.

Locations

Country Name City State
United Kingdom University of Bath Bath Somerset

Sponsors (1)

Lead Sponsor Collaborator
University of Bath

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in physical activity level (PAL) Physical activity will be assessed using a combined accelerometer and heart rate monitor (Actiheart) worn throughout the baseline period and weeks 3 and 4 of the intervention period Pre (day 0) and post (day 29)
Other Change in heart rate Heart rate will be assessed using an accelerometer (Actiheart) worn throughout the baseline period and weeks 3 and 4 of the intervention period Pre (day 0) and post (day 29)
Other Change in score on Pittsburgh Sleep Quality Index Questionnaire to assess sleep quality Pre (day 0) and post (day 29)
Other Change in score on EuroQuol EQ-5D-5L Questionnaire Questionnaire to assess health-related quality of life Pre (day 0) and post (day 29)
Other Change in Short Physical Performance Battery score Standard set of tests to measure physical function in elderly involving gait speed, chair stand and balance test Pre (day 0) and post (day 29)
Other Supplement acceptability as assessed by likability, taste and ease of compliance Acceptability of the supplement will be assessed via questionnaire using a 7-point Likert scale Post (day 29)
Other Change in adipose tissue protein expression Adipose tissue protein expression will be assessed by targeted immunoblotting. Pre (day 0) and post (day 29)
Primary Change in 24hr average glucose area under the curve (AUC) Glucose control will be measured using a continuous glucose monitoring device worn throughout the baseline period and weeks 3 and 4 of the intervention period. Change in 24h average glucose AUC will be assessed on 'matched meal and activity days' i.e. days during intervention and baseline that are matched for food intake and physical activity. 1 day during baseline period and 1 day during the intervention period
Secondary Change in glycemic variability Glucose control will be measured using continuous glucose monitoring device worn throughout the baseline period and weeks 3 and 4 of the intervention period. Change in glycemic variability will be assessed on 'matched meal and activity days' i.e. days during intervention and baseline that are matched for food intake and physical activity. 1 day during baseline period and 1 day during the intervention period
Secondary Change in serum fructosamine Measured in fasting blood sample by automated analyser (Daytona Rx) Pre (day 0) and post (day 29)
Secondary Change in fasting plasma glucose Measured in fasting blood sample by automated analyser (Daytona Rx) Pre (day 0) and post (day 29)
Secondary Change in fasting lipid profile concentrations Measured in fasting blood sample by automated analyser (Daytona Rx) Pre (day 0) and post (day 29)
Secondary Change in fasting plasma free fatty acids (FFA) Measured in fasting blood sample by automated analyser (Daytona Rx) Pre (day 0) and post (day 29)
Secondary Change in fasting plasma insulin Measured in fasting blood sample using a high-sensitivity human insulin enzyme-like immunosorbent assay (ELISA) Pre (day 0) and post (day 29)
Secondary Change in Insulin Sensitivity Index Calculated from fasting plasma insulin and fasting plasma glucose Pre (day 0) and post (day 29)
Secondary Change in Adipose tissue Insulin Resistance index (Adipo-IR) Calculated from fasting plasma insulin and fasting plasma FFA Pre (day 0) and post (day 29)
Secondary Change in body mass Measured using a digital body weight scales Pre (day 0) and post (day 29)
Secondary Change in waist and hip circumference Measured using a measurement tape Pre (day 0) and post (day 29)
Secondary Change in waist to hip ratio Calculated from waist and hip circumferences Pre (day 0) and post (day 29)
Secondary Change in fat mass and fat free mass Assessed by Dual Energy X-ray Absorptiometry (DEXA) scan Pre (day 0) and post (day 29)
Secondary Change in calf muscle density, quality and area Assessed by calf peripheral Quantitative Computed Tomography (pQCT) Pre (day 0) and post (day 29)
Secondary Change in blood pressure Measured using an automated blood pressure device. Both systolic and diastolic blood pressure will be measured Pre (day 0) and post (day 29)
Secondary Change in circulating adipokines and inflammatory cytokines Key inflammatory cytokines including CRP will be quantified by R-plex, U-plex and V-plex kits on a Mesoscale QuickPlex SQ120 Pre (day 0) and post (day 29)
Secondary Change in blood immune cell phenotype, function and activation Peripheral blood mononuclear cells (PBMCs) isolated from whole blood will be incubated with fluorophore-conjugated antibodies and analysed with a flow cytometer to examine the phenotype and cytokine production of immune cells Pre (day 0) and post (day 29)
Secondary Change in adipose tissue immune cell phenotype, function and activation Adipose tissue stromal vascular fraction (SVF) will be incubated with fluorophore-conjugated antibodies and analysed with a flow cytometer to examine the phenotype and cytokine production of immune cells Pre (day 0) and post (day 29)
Secondary Change adipose tissue adipokine and cytokine concentrations Adipose tissue explants will be cultured ex vivo for 3h. Concentrations of key adipokines and cytokines in supernatant will be quantified by R-plex, U-plex and V-plex kits on a Mesoscale QuickPlex SQ120 Pre (day 0) and post (day 29)
Secondary Change in adipose tissue gene expression Whole-tissue RNAseq Pre (day 0) and post (day 29)
Secondary Change in Digit-Symbol Substitution Test score This test will be administered using the computer-based app Inquisit6 Lab (Millisecond). The score reflects the number of correct symbols within the allowed time. Higher is better. Pre (day 0) and post (day 29)
Secondary Change in Stroop Test score This test will be administered using the computer-based app Inquisit6 Lab (Millisecond). The score reflects the number of correct responses and the response latency. Higher is better. Pre (day 0) and post (day 29)
Secondary Change in Trail Making Task score This test will be administered using the computer-based app Inquisit6 Lab (Millisecond). The score reflects the time taken to complete trails A and B. Lower is better. Pre (day 0) and post (day 29)
Secondary Change in Digit Span Test score This test will be administered using the computer-based app Inquisit6 Lab (Millisecond). The score reflects the maximum number of digits recalled correctly. Higher is better. Pre (day 0) and post (day 29)
Secondary Change in score on Montreal Cognitive Assessment (MoCA) The test will be administered by a trained researcher. Pre (day 0) and post (day 29)
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A